Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower ...

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in previously untreated mantle cell lymphoma.

The prognosis of patients with gastrointestinal stromal tumors is significantly impacted by gastrointestinal bleeding.

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...

Slowing down is linked to physiological changes, including reduced energy transformation in muscle cells and sluggish red ...

Dr. Ritu Salani discusses how patients with cervical cancer can advocate for their health and collaborate with their medical team to ensure the best care.

The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...